NeuroPace submits safety, effectiveness data from RNS System study to FDA
The Fly

NeuroPace submits safety, effectiveness data from RNS System study to FDA

NeuroPace (NPCE) announced FDA submission of three-year safety and effectiveness data from its prospective post-approval study of the RNS System in adults with drug-resistant focal epilepsy. The study enrolled more than three hundred patients from more than thirty leading Level 4 Comprehensive Epilepsy Centers in the United States, making it the largest prospectively enrolled trial in the field of neuromodulation for drug-resistant focal epilepsy.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App